Sleep Disorders

The director of the Center for Sleep and Cardiovascular Outcomes Research at University of Pittsburgh talked about a novel pharmacologic treatment that shows potential as an alternative to continuous positive airway pressure for sleep apnea. [WATCH TIME: 5 minutes]

The pediatric neurologist and sleep medicine specialist at Geisinger Medical Center discussed a presentation from SLEEP 2024 highlighting the impacts of narcolepsy and how patients try to mitigate their symptoms. [WATCH TIME: 5 minutes]

Catch up on any of the neurology news headlines you may have missed over the course of May 2024, compiled all into one place by the NeurologyLive® team.

Here's some of what is coming soon to NeurologyLive® this week.

Neurology News Network. for the week ending June 9, 2024. [WATCH TIME: 4 minutes]

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on stroke and large hemispheric infarction.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending June 7, 2024.

A recent study showed that patients with isolated REM sleep behavior disorder had a high risk of neurodegenerative parkinsonian disorders or dementia based on electronic health records.

Researchers presented an innovative multi-task learning paradigm that leveraged deep learning, night sleep EEG data, sleep stage labels, and covariates to simultaneously predict cognitive performance in an older patient cohort.

Daridorexant, an FDA-approved dual orexin receptor antagonist, had a dose-response relationship observed at month 1 on all 4 efficacy end points for all doses tested.

A recent study showed that patients with obstructive sleep apnea experience significant negative impacts on their physical, social, and emotional functioning.

The pulmonologist at Rush Health and immediate past president of the American Academy of Sleep Medicine provided perspective on some of the intriguing changes to sleep medicine and where the field is headed in the coming years.

A recent study showed that obstructive sleep apnea may impact the long-term disruption of the glymphatic system function and the development of neurodegenerative diseases.

Assessing doses of 3 mg doxepin, results revealed non-statistically significant improvements in latency to sleep onset and latency to persistent sleep that were observed across patients above and at or below the median baseline values.

In a clinical cohort study, approximately 89% of patients with obstructive sleep apnea classified as “Probably-normal” or “Likely-normal" in assessment of sleep biomarker-based neurodegenerative disorder risk.

The pediatric neurologist at the University of California, Davis, provided perspective on some of the mechanistic links between sleep and neurodevelopmental disorders. [WATCH TIME: 3 minutes]

A phase 3 trial plans to investigate the efficacy and safety of AD109, a novel oral medication, for treating obstructive sleep apnea in patients who cannot tolerate continuous positive airway pressure therapy.

Regardless of whether patients were treatment-naïve or taking alerting agents, the safety profile of low-sodium oxybate remained true, with treatment-emergent adverse events attributing to less than 4% of study discontinuations.

Overall, most patients reported satisfaction with cognitive behavioral therapy approach, with completion of lessons associated with a decrease in Fatigue Severity Scale.

The sleep medicine specialist at the University of California, San Francisco provided perspective on some of the innovative therapeutic strategies in development for patients with obstructive sleep apnea. [WATCH TIME: 5 minutes]

A recent study demonstrated no significant difference in sleep efficiency between pediatric patients with epilepsy who used self-help strategies for sleep aids and those who did not.

Here's some of what is coming soon to NeurologyLive® this week.

A recent study presented at SLEEP 2024 showed that depression in patients with isolated REM sleep behavior disorder significantly increased the risk of conversion to neurodegenerative diseases.

Those on low-sodium oxybate, regardless of psychiatric comorbidity status, outperformed placebo on a number of outcomes, including Epworth Sleepiness Scale and weekly cataplexy attacks.

A majority of the small cohort of patients with SMA did not need a polysomnogram at 1 year because respiratory pathology was not a concern, attributable to improvements from disease-modifying therapies.